WO2006000830A3 - Cells expressing a modified t cell receptor - Google Patents

Cells expressing a modified t cell receptor Download PDF

Info

Publication number
WO2006000830A3
WO2006000830A3 PCT/GB2005/002570 GB2005002570W WO2006000830A3 WO 2006000830 A3 WO2006000830 A3 WO 2006000830A3 GB 2005002570 W GB2005002570 W GB 2005002570W WO 2006000830 A3 WO2006000830 A3 WO 2006000830A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell receptor
modified
cells expressing
tcr
cell
Prior art date
Application number
PCT/GB2005/002570
Other languages
French (fr)
Other versions
WO2006000830A2 (en
Inventor
Bent Karsten Jakobsen
Original Assignee
Avidex Ltd
Bent Karsten Jakobsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0414499A external-priority patent/GB0414499D0/en
Priority claimed from GB0421831A external-priority patent/GB0421831D0/en
Priority claimed from GB0511123A external-priority patent/GB0511123D0/en
Priority to DE200560022595 priority Critical patent/DE602005022595D1/en
Priority to EP05756424A priority patent/EP1791865B1/en
Priority to DK05756424T priority patent/DK1791865T3/en
Application filed by Avidex Ltd, Bent Karsten Jakobsen filed Critical Avidex Ltd
Priority to AT05756424T priority patent/ATE475669T1/en
Priority to US11/597,252 priority patent/US8361794B2/en
Priority to JP2007518692A priority patent/JP5563194B2/en
Publication of WO2006000830A2 publication Critical patent/WO2006000830A2/en
Publication of WO2006000830A3 publication Critical patent/WO2006000830A3/en
Priority to US13/716,817 priority patent/US9115372B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

This invention provides a cell presenting at least one T cell receptor (TCR) anchored to the membrane by a transmembrane sequence, said TCR comprising an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs.
PCT/GB2005/002570 2004-06-29 2005-06-29 Cells expressing a modified t cell receptor WO2006000830A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2007518692A JP5563194B2 (en) 2004-06-29 2005-06-29 Cells expressing modified T cell receptors
US11/597,252 US8361794B2 (en) 2004-06-29 2005-06-29 Cells expressing a modified T cell receptor
AT05756424T ATE475669T1 (en) 2004-06-29 2005-06-29 CELLS EXPRESSING A MODIFIED T-CELL RECEPTOR
EP05756424A EP1791865B1 (en) 2004-06-29 2005-06-29 Cells expressing a modified t cell receptor
DK05756424T DK1791865T3 (en) 2004-06-29 2005-06-29 Cells expressing a modified T cell receptor
DE200560022595 DE602005022595D1 (en) 2004-06-29 2005-06-29 A MODIFIED T-CELL RECEPTOR EXPRESSING CELLS
US13/716,817 US9115372B2 (en) 2004-06-29 2012-12-17 Cells expressing modified T cell receptor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0414499A GB0414499D0 (en) 2004-06-29 2004-06-29 Substances
GB0414499.4 2004-06-29
GB0421831.9 2004-10-01
GB0421831A GB0421831D0 (en) 2004-10-01 2004-10-01 Substances
GB0511123A GB0511123D0 (en) 2005-06-01 2005-06-01 Substances
GB0511123.2 2005-06-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/597,252 A-371-Of-International US7569435B2 (en) 2004-01-24 2005-01-21 Transistor manufacture
US13/716,817 Division US9115372B2 (en) 2004-06-29 2012-12-17 Cells expressing modified T cell receptor

Publications (2)

Publication Number Publication Date
WO2006000830A2 WO2006000830A2 (en) 2006-01-05
WO2006000830A3 true WO2006000830A3 (en) 2006-07-06

Family

ID=35782159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/002570 WO2006000830A2 (en) 2004-06-29 2005-06-29 Cells expressing a modified t cell receptor

Country Status (7)

Country Link
US (2) US8361794B2 (en)
EP (1) EP1791865B1 (en)
JP (1) JP5563194B2 (en)
AT (1) ATE475669T1 (en)
DE (1) DE602005022595D1 (en)
DK (1) DK1791865T3 (en)
WO (1) WO2006000830A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
US12031975B2 (en) 2018-10-31 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
KR101130597B1 (en) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 T-cell receptor and nucleic acid encoding the receptor
CN101330830B (en) 2005-10-18 2016-01-20 国家犹太健康中心 Condition immortalization long-term stem cells and preparation and use the method for described cell
US8088379B2 (en) * 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US20100035764A1 (en) * 2006-09-26 2010-02-11 St. Jude Children's Research Hospital Methods and compositions for monitoring t cell receptor diversity
WO2008038002A2 (en) * 2006-09-29 2008-04-03 Medigene Limited T cell therapies
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
AU2008304555A1 (en) * 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified T cell receptors and related materials and methods
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
EP2598528A1 (en) 2010-07-28 2013-06-05 Immunocore Ltd. T cell receptors
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP3505537A1 (en) 2012-05-07 2019-07-03 Trustees of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
EP2877189B1 (en) 2012-07-20 2021-01-06 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
GB201309421D0 (en) 2013-05-24 2013-07-10 Imp Innovations Ltd Polypeptides
GB201313377D0 (en) 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
KR20160079854A (en) 2013-10-31 2016-07-06 프레드 헛친슨 켄서 리서치 센터 Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (en) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 Combination therapy with neoantigen vaccine
DK3083671T3 (en) 2013-12-20 2020-12-07 Hutchinson Fred Cancer Res LABELED CHIMARY EFFECTOR MOLECULES AND RECEPTORS THEREOF
WO2015123496A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
BR112016021004A2 (en) * 2014-03-14 2018-01-23 Immunocore Limited particle library; unnatural isolated t (tcr) cell receptor; use of a library; a method of obtaining a t-cell receptor that specifically binds to a peptide antigen; nucleic acid; method of constructing a particle library; a method of obtaining a t-cell receptor that specifically binds to a peptide antigen; and particle
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
CA2955984A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
EP3216801B1 (en) * 2014-11-07 2020-01-01 Guangdong Xiangxue Life Sciences, Ltd. Soluble heterodimeric t cell receptor, and preparation method and use thereof
GB201421096D0 (en) 2014-11-27 2015-01-14 Imp Innovations Ltd Genome editing methods
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
CA2978186A1 (en) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
US20180355318A1 (en) 2015-04-29 2018-12-13 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
MX2017014700A (en) 2015-05-20 2018-08-15 Broad Inst Inc Shared neoantigens.
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516272D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
CN108884164B (en) 2016-02-25 2022-12-27 细胞医学瑞士公司 Modified cells for immunotherapy
US10982136B2 (en) 2016-02-26 2021-04-20 The Regents Of The University Of California Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
US20190119387A1 (en) 2016-04-05 2019-04-25 Glaxosmithkline Intellectual Property Development Limited Inhibition of tgfbeta in immunotherapy
KR102542533B1 (en) 2016-04-14 2023-06-13 프레드 허친슨 캔서 센터 Compositions and methods for programming therapeutic cells using targeting nucleic acid nanotransporters
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
EP3452499A2 (en) 2016-05-06 2019-03-13 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
MA45455A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc PROCESS FOR IDENTIFYING PEPTIDIC EPITOPES, MOLECULES THAT BIND TO SUCH EPITOPES AND ASSOCIATED USES
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
JP2019532017A (en) 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター Multiple bispecific binding domain constructs exhibiting different epitope binding for treating cancer
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
US11235076B2 (en) 2016-08-29 2022-02-01 Fred Hutchinson Cancer Research Center Chelating platform for delivery of radionuclides
EP3509595B1 (en) 2016-09-06 2022-11-02 The Regents of The University of California Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
EP4290532A3 (en) 2016-09-29 2024-03-20 The Regents of the University of California Separation of metal ions by liquid-liquid extraction
MX2019003768A (en) 2016-10-03 2019-06-24 Juno Therapeutics Inc Hpv-specific binding molecules.
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
MA46649A (en) 2016-10-13 2019-08-21 Juno Therapeutics Inc METHODS AND COMPOSITIONS OF IMMUNOTHERAPY INVOLVING MODULATORS OF THE TRYPTOPHAN METABOLIC PATHWAY
CN110139669A (en) 2016-11-03 2019-08-16 朱诺治疗学股份有限公司 The combination treatment of T cell therapy and BTK inhibitor
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
CA3045017A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
BR112019011025A2 (en) 2016-12-03 2019-10-08 Juno Therapeutics Inc T cell modulation methods
MX2019006286A (en) 2016-12-03 2020-02-07 Juno Therapeutics Inc Methods for determining car-t cells dosing.
CN110249046A (en) 2016-12-05 2019-09-17 朱诺治疗学股份有限公司 The generation of engineering cell for adoptive cellular therapy
CN110691792A (en) 2017-01-10 2020-01-14 朱诺治疗学股份有限公司 Epigenetic analysis of cell therapies and related methods
CA3049652A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
WO2018132739A2 (en) 2017-01-13 2018-07-19 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
US11517627B2 (en) 2017-01-20 2022-12-06 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN116693695A (en) 2017-02-12 2023-09-05 百欧恩泰美国公司 HLA-based methods and compositions and uses thereof
IL268349B1 (en) 2017-02-17 2024-04-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
JP7228522B2 (en) 2017-02-27 2023-02-24 ジュノー セラピューティクス インコーポレイテッド Compositions, articles of manufacture, and methods for dosing in cell therapy
AU2018234640B2 (en) 2017-03-14 2024-03-14 Juno Therapeutics, Inc. Methods for cryogenic storage
JP2020511136A (en) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター Immunomodulatory fusion proteins and uses thereof
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
CA3056261A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
CA3059584A1 (en) 2017-04-14 2018-10-18 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
EP3612629A1 (en) 2017-04-18 2020-02-26 The Broad Institute, Inc. Compositions for detecting secretion and methods of use
SG11201910143TA (en) 2017-05-01 2019-11-28 Juno Therapeutics Inc Combination of a cell therapy and an immunomodulatory compound
JP7486953B2 (en) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー Compositions and methods for cell-targeted therapy
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
MA48781A (en) 2017-06-02 2020-04-08 Juno Therapeutics Inc ARTICLES OF MANUFACTURING AND PROCESSES RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY
CA3065930A1 (en) 2017-06-07 2018-12-13 Intrexon Corporation Expression of novel cell tags
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
EP3644721A1 (en) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
WO2019027850A1 (en) 2017-07-29 2019-02-07 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
JP6731114B2 (en) 2017-08-03 2020-07-29 タイガ バイオテクノロジーズ，インク． Methods and compositions for the treatment of melanoma
JP2020530294A (en) 2017-08-09 2020-10-22 ジュノー セラピューティクス インコーポレイテッド Methods and compositions for preparing genetically engineered cells
MX2020001490A (en) 2017-08-09 2020-08-06 Juno Therapeutics Inc Methods for producing genetically engineered cell compositions and related compositions.
EP3441461A1 (en) 2017-08-11 2019-02-13 Baylor College of Medicine Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
AU2018326875A1 (en) 2017-09-04 2020-03-19 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
WO2019051335A1 (en) 2017-09-07 2019-03-14 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
CA3073848A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
MX2020003536A (en) 2017-10-03 2020-09-14 Juno Therapeutics Inc Hpv-specific binding molecules.
EP3692058A1 (en) 2017-10-06 2020-08-12 Oslo Universitetssykehus HF Chimeric antigen receptors
US11732257B2 (en) 2017-10-23 2023-08-22 Massachusetts Institute Of Technology Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
CN111542596A (en) 2017-11-01 2020-08-14 朱诺治疗学股份有限公司 Methods of producing therapeutic compositions of engineered cells
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US20210254000A1 (en) 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
EP3704251A2 (en) 2017-11-01 2020-09-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
CN111556893A (en) 2017-11-06 2020-08-18 爱迪塔斯医药股份有限公司 Methods, compositions, and components for CRISPR-CAS9 editing of CBLB in immunotherapy T cells
MX2020004568A (en) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor.
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
MA51210A (en) 2017-12-01 2020-10-07 Juno Therapeutics Inc METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS
BR112020011215A2 (en) 2017-12-08 2020-11-17 Juno Therapeutics Inc process for producing a modified t-cell composition
CN112203680A (en) 2017-12-08 2021-01-08 朱诺治疗学股份有限公司 Phenotypic markers for cell therapy and related methods
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019152743A1 (en) 2018-01-31 2019-08-08 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
MA52193A (en) 2018-04-05 2021-02-17 Juno Therapeutics Inc T-LYMPHOCYTE RECEPTORS AND MODIFIED CELLS EXPRESSING THEM
MX2020010461A (en) 2018-04-05 2021-01-15 Juno Therapeutics Inc T cells expressing a recombinant receptor, related polynucleotides and methods.
BR112020020245A2 (en) 2018-04-05 2021-04-06 Editas Medicine, Inc. METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210363216A1 (en) 2018-05-14 2021-11-25 Immunocore Limited Bifunctional binding polypeptides
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
MX2021001519A (en) 2018-08-09 2021-05-27 Juno Therapeutics Inc Methods for assessing integrated nucleic acids.
MX2021001523A (en) 2018-08-09 2021-05-27 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof.
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US20210355522A1 (en) 2018-08-20 2021-11-18 The Broad Institute, Inc. Inhibitors of rna-guided nuclease activity and uses thereof
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
BR112021003631A2 (en) 2018-09-05 2021-05-18 Glaxosmithkline Intellectual Property Development Limited t cell modification
MA53612A (en) 2018-09-11 2021-09-15 Juno Therapeutics Inc METHODS FOR ANALYZING MODIFIED CELLULAR COMPOSITIONS BY MASS SPECTROMETRY
EP4268831A3 (en) 2018-09-12 2024-05-22 Fred Hutchinson Cancer Center Reducing cd33 expression to selectively protect therapeutic cells
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
KR20210098450A (en) 2018-10-31 2021-08-10 주노 테라퓨틱스 게엠베하 Method for cell selection and stimulation and device therefor
BR112021008738A2 (en) 2018-11-06 2021-11-03 Juno Therapeutics Inc Process to produce genetically engineered t cells
SG11202104411VA (en) 2018-11-08 2021-05-28 Juno Therapeutics Inc Methods and combinations for treatment and t cell modulation
SG11202105380RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
SG11202105502RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
EP3899954A4 (en) 2018-12-21 2022-09-14 BioNTech US Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
EP3931310A1 (en) 2019-03-01 2022-01-05 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
EP3980530A1 (en) 2019-06-07 2022-04-13 Juno Therapeutics, Inc. Automated t cell culture
AU2020293230A1 (en) 2019-06-12 2022-01-27 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
AU2020298572A1 (en) 2019-07-02 2021-11-18 Fred Hutchinson Cancer Center Recombinant Ad35 vectors and related gene therapy improvements
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
AU2020377043A1 (en) 2019-10-30 2022-06-02 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
CN115398231A (en) 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 Methods related to toxicity and response associated with cell therapy for treatment of B cell malignancies
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
JP2023512209A (en) 2020-01-28 2023-03-24 ジュノー セラピューティクス インコーポレイテッド Methods for T cell transduction
CN115087489A (en) 2020-02-14 2022-09-20 艾达普特免疫有限公司 Method for treating cancer or tumor
EP4121453A2 (en) 2020-03-20 2023-01-25 Orna Therapeutics, Inc. Circular rna compositions and methods
CA3177181A1 (en) * 2020-03-27 2021-09-30 2Seventy Bio, Inc. T cell receptors
AU2021244937A1 (en) 2020-03-27 2022-11-03 Mendus B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4127139A1 (en) 2020-03-27 2023-02-08 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021231661A2 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
KR20230042283A (en) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 Engineered T cells conditionally expressing recombinant receptors, related polynucleotides and methods
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
US20220168407A1 (en) 2020-11-05 2022-06-02 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
AU2021389909A1 (en) 2020-11-24 2023-06-22 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CN116867799A (en) 2021-02-10 2023-10-10 上海吉倍生物技术有限公司 Ras G13D mutant epitope peptide and T cell receptor for recognizing Ras G13D mutant
JP2024507929A (en) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド Recombinant vectors containing polycistronic expression cassettes and methods for their use
US20240150711A1 (en) 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
JP2024509853A (en) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Combination of T cell therapy and DGK inhibitor
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
IL307262A (en) 2021-03-29 2023-11-01 Juno Therapeutics Inc Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
WO2022234009A2 (en) 2021-05-06 2022-11-10 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
IL308746A (en) 2021-06-10 2024-03-01 Orna Therapeutics Inc Circular rna compositions and methods
WO2023056033A1 (en) 2021-09-30 2023-04-06 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
TW202334080A (en) 2021-11-08 2023-09-01 美商歐納醫療公司 Lipid nanoparticle compositions for delivering circular polynucleotides
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
US20240052049A1 (en) 2022-06-24 2024-02-15 Orna Therapeutics, Inc. Circular rna encoding chimeric antigen receptors targeting bcma
WO2024006960A1 (en) 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024129982A2 (en) 2022-12-15 2024-06-20 Orna Therapeutics, Inc. Circular rna compositions and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055366A1 (en) * 2000-01-13 2001-08-02 Het Nederlands Kanker Instituut T cell receptor libraries
WO2003020763A2 (en) * 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
US6558672B1 (en) * 1993-06-14 2003-05-06 The United States Of America As Represented By The Department Of Health And Human Services Methods of making recombinant disulfide-stabilized polypeptide fragments having binding specificity
WO2004074322A1 (en) * 2003-02-22 2004-09-02 Avidex Ltd Modified soluble t cell receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ539225A (en) * 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558672B1 (en) * 1993-06-14 2003-05-06 The United States Of America As Represented By The Department Of Health And Human Services Methods of making recombinant disulfide-stabilized polypeptide fragments having binding specificity
WO2001055366A1 (en) * 2000-01-13 2001-08-02 Het Nederlands Kanker Instituut T cell receptor libraries
WO2003020763A2 (en) * 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
WO2004074322A1 (en) * 2003-02-22 2004-09-02 Avidex Ltd Modified soluble t cell receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI Z G ET AL: "STRUCTURAL MUTATIONS IN THE CONSTANT REGION OF THE T-CELL ANTIGEN RECEPTOR (TCR)BETA CHAIN AND THEIR EFFECT ON TCR ALPHA AND BETA CHAIN INTERACTION", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 88, no. 4, August 1996 (1996-08-01), pages 524 - 530, XP008028134, ISSN: 0019-2805 *
PECORARI F ET AL: "Folding, heterodimeric association and specific peptide recognition of a murine alphabeta T-cell receptor expressed in Escherichia coli", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 285, no. 4, 29 January 1999 (1999-01-29), pages 1831 - 1843, XP004457383, ISSN: 0022-2836 *
REITER Y ET AL: "CONSTRUCTION OF A FUNCTIONAL DISULFIDE-STABILIZED TCR FV INDICATES THAT ANTIBODY AND TCR FV FRAMEWORKS ARE VERY SIMILAR IN STRUCTURE", IMMUNITY, CELL PRESS, US, vol. 2, no. 3, March 1995 (1995-03-01), pages 281 - 287, XP009004075, ISSN: 1074-7613 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
US12031975B2 (en) 2018-10-31 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy

Also Published As

Publication number Publication date
JP2008504043A (en) 2008-02-14
EP1791865A2 (en) 2007-06-06
US20100047220A1 (en) 2010-02-25
DK1791865T3 (en) 2010-11-01
US20130189309A1 (en) 2013-07-25
US8361794B2 (en) 2013-01-29
EP1791865B1 (en) 2010-07-28
ATE475669T1 (en) 2010-08-15
JP5563194B2 (en) 2014-07-30
US9115372B2 (en) 2015-08-25
WO2006000830A2 (en) 2006-01-05
DE602005022595D1 (en) 2010-09-09

Similar Documents

Publication Publication Date Title
WO2006000830A3 (en) Cells expressing a modified t cell receptor
WO2009091826A3 (en) Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
GB0304068D0 (en) Substances
NO20041325L (en) substances
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
EP2808393A3 (en) Fucosylation-deficient cells
ATE548677T1 (en) IONIC LIQUID
WO2008019004A3 (en) Roofing membrane
TWI366940B (en) Polymer electrolyte material, polymer electrolyte component, membrane electrolyte complex, and polymer electrolyte fuel cell
WO2009046407A3 (en) B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
WO2006023148A3 (en) Genetically modified human natural killer cell lines
NZ553118A (en) Anti-FC-gamma RIIB receptor antibody and uses therefor
WO2008042814A3 (en) Mart-1 t cell receptors
WO2009100040A3 (en) Cell lines expressing gaba receptor and methods using them
WO2007124361A3 (en) Soluble b7-h1
WO2008097870A3 (en) Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc- asgpr)
EP3112376A3 (en) Bifunctional polypeptides
WO2007047988A3 (en) Chimeric human sweet-umami and umami-sweet taste receptors
WO2006076031A3 (en) Solid polymer electrolyte membranes
WO2021030153A3 (en) Engineered t cell receptors and uses thereof
WO2007051063A3 (en) Gpcr expressing cell lines and antibodies
WO2009055509A3 (en) Cholesterol consensus motif of membrane proteins
WO2007102736A3 (en) Interfering in activation of an immune cell by influencing interaction of lair and collagen.
DK1907536T3 (en) Cell line for the production of coronaviruses
HK1117595A1 (en) Method for detecting autoimmune antibodies against tsh receptors and novel tsh-receptor chimaeras

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005756424

Country of ref document: EP

Ref document number: 2007518692

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 2005756424

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11597252

Country of ref document: US